Phase 2 N=35 RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer
Hormone Refractory Prostate Cancer
Primary: Biochemical Response Rate — 0 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=34 Telemedicine To Provide Inflammatory Bowel Disease Outpatient Care
Inflammatory Bowel Disease · Ulcerative Colitis · Crohn's Disease
Primary: Patient Clinical Experience — 1.2; 1.3 units on a scale — p=<0.05
Phase 2 N=236 Self Hypnotic Relaxation As An Adjunct To Local Anesthesia During Large Core Breast Biopsy
Breast Cancer · Anxiety · Pain
Primary: Anxiety Ratings at Specified Time Point During the Procedure — 4.5; 5; 5 units on a scale
Phase 2 N=30 An add-on Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-epileptic Drugs (AEDs)
Refractory Partial Seizures
Primary: Maximum Tolerated Dose (MTD) — 0; 2; 1; 6 Participants
Phase 2 N=198 Cavitation Ultrasound in Treatment of Patients With PCOS
PCOS
Primary: Clinical Pregnancy Rate — 12; 5; 16 participants
Phase 2 N=62 S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
Prostate Cancer
Primary: Confirmed Prostate-Specific Antigen (PSA) Response — 3.8 percentage of participants
Phase 2 N=95 Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
Acute Myeloid Leukemia · Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Primary: Remission Induction Response — 62; 4 participants
Phase 2 N=98 S0410 Tandem Stem Cell Transplantation in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma
Lymphoma
Primary: 2-year Progression-free Survival — 59 percentage of participants
Phase 2 N=2,032 Message Framing for Telephone Quitline Callers
Smoking · Nicotine Dependence
Primary: Quit Attempt — 101; 132 participants
Phase 2 N=40 Low-Dose Naltrexone Combined With Bupropion to Stop Smoking With Less Weight Gain
Smoking · Nicotine Dependence
Primary: Smoking Cessation — 6; 6 participants
Phase 2 N=68 S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
Lymphoma
Primary: 2-year Progression-free Survival in Patients Treated With Rituximab-CHOP-bortezomib Induction Therapy (RCHOP-V) Followed by Bortezomib Maintenance Therapy (VM) — 62…
Phase 2 N=165 Efficacy of Proton Pump Inhibitor in Prevention of Clopidogrel-related Peptic Ulcer
Peptic Ulcer
Primary: Recurrent Peptic Ulcer — 1; 9 participants
Phase 2 N=150 Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
Ovarian Cancer
Primary: Progression-free Survival (PFS) — 13.7; 8.4 months
Phase 2 N=23 Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan
Glioblastoma · Gliosarcoma
Primary: The Primary Outcome Measure is 6 Month Progression-free Survival. — 0; 7.7 percentage of participants
Phase 2 N=70 Levulan PDT Versus Vehicle for Extremity Actinic Keratoses (AK)
Keratosis, Actinic
Primary: Lesion Clearance Rate — 88.7; 70.0; 16.7; 5.6 percentage of lesions cleared